OBJECTIVES : Hypertensive disorders represent major causes of pregnancy related maternal mortality worldwide. Preeclampsia affects 3–4% of all pregnancies in Ukraine. There is a necessary a list of proven medicines.

METHODS : Comparative analysis of Ukraine clinical guidelines, NICE and ESH/ESC guidelines, analysis of registered antihypertensive drugs, cost analysis.

RESULTS : We analyzed the list of antihypertensive drugs included in the Ukrainian guidelines, NICE an ESH/ESC guidelines as well. It was established, that in Ukraine no registered medicines such as labetalol, oxiprenolol, hydralazine, which are included in guidelines. Methyldopa as a first-line medicine for the treatment of pregnant hypertension, there is registered only one by european producer. We calculated the direct costs for the treatment course methyldopa per 1 pregnant woman (3 months), it was 541,2 UAH (19,2 $). These costs are high for pregnant women out-of-pocket.

Oral nifedipine and verapamil are frequently as second line used for the treatment of hypertension in pregnancy The nifedipine is registered in 15 trade names, of which 67,7% are foreign producers in market. We calculated the cost per treatment was 50.5-81.2 UAH (1.8-2.9 $) by ukrainian producer, cost was 226.1- 543.3 UAH ($ 8.1- $ 19.4) by foreign. Verapamil is registered in 10 TN, of which 50% are foreign. The cost per treatment was 30.3 - 54.8 UAH (1.1 - 2.0 $) for domestic drugs and 166.1 USD (5.9 USD) for a foreign. Cost for foreign drugs are 5,5 times higher.

CONCLUSIONS : For the good treatment of hypertension in pregnancy according to the ESH/ESC and Ukraine guidelines,it is necessary to register the market of these drugs in order to ensure their availability: labetalol, oxiprenolol, hydralazin. It is also necessary to introduce a domestic methyldopa for reducing the cost of patient and budget. Perspective is to include in the reimbursement list these antihypertensive drugs for budget financing treatment of hypertension in pregnancy in Ukraine.